

Contents

The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course	1
Rebecca Kuepper, Mette Skinbjerg, and Anissa Abi-Dargham	
Role of Dopamine D₂ Receptors for Antipsychotic Activity	27
Nathalie Ginovart and Shitij Kapur	
Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs	53
Kevin N. Boyd and Richard B. Mailman	
Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics	87
Herbert Y. Meltzer	
Managing the Prodrome of Schizophrenia	125
W. Wolfgang Fleischhacker and Alexander M. Simma	
Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity	135
David J. Heal, Jane Gosden, Helen C. Jackson, Sharon C. Cheetham, and Sharon L. Smith	
Medical Needs in the Treatment of Psychotic Disorders	165
F. Markus Leweke, Thorsten M. Odorfer, and J. Malte Bumb	
Antipsychotics in the Treatment of Bipolar Disorder	187
Jaskaran Singh, Guang Chen, and Carla M. Canuso	
The Pharmacogenetics of Antipsychotic Treatment	213
Gavin P. Reynolds	

Interactions and Monitoring of Antipsychotic Drugs 241
Christoph Hiemke and Bruno Pfulmann

Delivery Systems and Dosing for Antipsychotics 267
Cara R. Rabin and Steven J. Siegel

Imaging as Tool to Investigate Psychoses and Antipsychotics 299
Jan Booij and Thérèse van Amelsvoort

Biomarkers for Antipsychotic Therapies 339
Emilio Merlo Pich, Gabriel Vargas, and Enrico Domenici

Behavioral Animal Models of Antipsychotic Drug Actions 361
Daria Peleg-Raibstein, Joram Feldon, and Urs Meyer

Index 407



<http://www.springer.com/978-3-642-25760-5>

Current Antipsychotics

Gross, G.; Geyer, M.A. (Eds.)

2012, X, 418 p., Hardcover

ISBN: 978-3-642-25760-5